Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
Glucagon
Metabolic & Weight Loss
Molecular Dossier
- Rank Index: 84
- Status: FDA Approved
- What does this mean?
- Molecular Structure: MW: 3482.8 Da | 29 AA | CAS: 16941-32-5 | Sequence: His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr
About Glucagon
Glucagon is a 29-amino acid pancreatic hormone secreted by alpha-cells of the islets of Langerhans in response to hypoglycemia, fasting, exercise, and protein ingestion. It is insulin's primary counter-regulatory hormone, acting at the glucagon receptor (GcgR) to stimulate hepatic glycogenolysis and gluconeogenesis, raising blood glucose rapidly. Beyond this classic role, glucagon is now recognized as a pleiotropic metabolic hormone with major effects outside the liver: in adipose tissue it stimulates lipolysis and thermogenesis; in the heart it increases cardiac output and exerts positive inotropic effects; in the gut it slows motility; and in the brain it may regulate appetite and reward circuitry. The renewed research interest in glucagon stems from the GLP-1/glucagon dual agonist class: survodutide, pemvidutide, cotadutide, and oxyntomodulin all co-activate GcgR, and tirzepatide has modest GcgR activity at higher doses. Researchers now argue that glucagon receptor co-agonism is responsible for the superior fat loss and hepatic benefits of dual agonists versus GLP-1 monotherapy — specifically through thermogenesis and direct hepatic fat oxidation that GLP-1R activation alone cannot provide. Paradoxically, blocking glucagon (glucagon receptor antagonists) was pursued as a diabetes treatment but produced unacceptable hepatic side effects, suggesting glucagon's liver-directed effects are more complex than simple hyperglycemia induction. Exogenous glucagon is FDA-approved for hypoglycemia rescue (GlucaGen, Baqsimi nasal spray) and diagnostic use. Understanding glucagon biology is essential context for the entire modern obesity/metabolic pharmacology landscape.
Clinical Focus
Glycogenolysis, Hepatic Glucose Output, Counter-Regulatory Hormone
Archival Aliases
Glucagon peptide, GlucaGen, Baqsimi, Counter-regulatory hormone
Frequently Asked Questions
What are the FDA-approved forms of glucagon?
Three FDA-approved glucagon products are available: (1) GlucaGen HypoKit (glucagon hydrochloride injection, Novo Nordisk) — powder for reconstitution, 1 mg intramuscular or subcutaneous injection for hypoglycemia rescue. (2) Gvoke (glucagon injection, Xeris) — a ready-to-use pre-filled autoinjector containing 0.5–1 mg in a stable liquid formulation, eliminating the reconstitution step. (3) Baqsimi (glucagon nasal powder, Eli Lilly/Amphastar) — 3 mg intranasal glucagon, FDA-approved in 2019 as the first nasal glucagon; particularly valuable for caregivers who may have difficulty injecting an unconscious patient. All three are approved for severe hypoglycemia rescue in insulin-dependent diabetes.
What role does glucagon play in thermogenesis and fat burning?
Glucagon directly stimulates thermogenesis via two mechanisms: (1) In brown and beige adipose tissue, GcgR activation upregulates uncoupling protein 1 (UCP-1) expression and increases fatty acid oxidation, generating heat rather than ATP. (2) In the liver, glucagon stimulates beta-oxidation of fatty acids and ketogenesis, increasing metabolic rate. These thermogenic effects are modest at physiological concentrations but become clinically meaningful at the supraphysiological receptor activation achieved by dual agonists. Research suggests glucagon accounts for approximately 1–2% increase in resting energy expenditure per dose in humans — not dramatic in isolation, but additive with GLP-1R-mediated caloric reduction in dual agonist protocols.
Why is glucagon receptor co-agonism being added to GLP-1 drugs?
GLP-1R monotherapy (semaglutide, liraglutide) produces weight loss primarily through appetite suppression and reduced caloric intake — the metabolic rate adapts downward ("adaptive thermogenesis"), partially offsetting the caloric deficit. Adding GcgR co-agonism directly counteracts this metabolic adaptation by stimulating hepatic fat oxidation, BAT thermogenesis, and lipolysis — mechanisms that GLP-1R activation cannot access. Clinical data supports this: survodutide and cotadutide (GLP-1R/GcgR dual agonists) show greater liver fat reduction and comparable or superior body weight loss versus GLP-1R monotherapy, with particular advantages in MASH (metabolic dysfunction-associated steatohepatitis) where direct hepatic fat oxidation is mechanistically important.
How is glucagon used in medical emergencies beyond hypoglycemia rescue?
Beyond hypoglycemia, glucagon has several other approved or studied clinical applications: (1) Beta-blocker overdose: glucagon bypasses the blocked beta-adrenergic receptors to directly increase cAMP in cardiac cells, restoring heart rate and contractility via GcgR — a unique and critical use in cardiology emergency medicine. (2) Calcium channel blocker overdose: similar mechanism, using glucagon's positive inotropic effects to support cardiac output. (3) Diagnostic gastrointestinal imaging: low-dose glucagon (0.5–2 mg IV) causes transient hypotonia of gastrointestinal smooth muscle, improving image quality in MRI and CT colonography. (4) Food bolus esophageal obstruction: glucagon relaxes the lower esophageal sphincter, sometimes dislodging food impactions. These non-metabolic applications reflect glucagon's broad receptor distribution outside the liver.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | MW: 3482.8 Da | 29 AA | CAS: 16941-32-5 | Sequence: His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr |
| Primary Pathway | Metabolic & Weight Loss |
| Research Phase | FDA Approved |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-15